Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 1841Neoplasms 1230Colorectal Neoplasms 1046Carcinoma, Non-Small-Cell Lung 996Stomach Neoplasms 787Carcinoma, Hepatocellular 780Lung Neoplasms 756Prostatic Neoplasms 682Pancreatic Neoplasms 567Rectal Neoplasms 444Colonic Neoplasms 401Neoplasm Metastasis 400Ovarian Neoplasms 399Uterine Cervical Neoplasms 395Recurrence 380Leukemia, Myeloid, Acute 367Esophageal Neoplasms 352Multiple Myeloma 340Lymphoma 330Head and Neck Neoplasms 326Melanoma 306Precursor Cell Lymphoblastic Leukemia-Lymphoma 288Brain Neoplasms 263Urinary Bladder Neoplasms 249Nasopharyngeal Carcinoma 221Liver Neoplasms 221Leukemia 217Lymphoma, Large B-Cell, Diffuse 213Polycystic Ovary Syndrome 206Squamous Cell Carcinoma of Head and Neck 200

Interventions

icotinib 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × EGF-R Positive Non-Small Cell Lung Cancer × Clear all
NCT06352502 2024-04-08

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Tang-Du Hospital

Unknown
30 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
36 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
60 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡